Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
21.55
+0.10 (0.47%)
Apr 29, 2025, 4:00 PM EDT - Market closed
Dianthus Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Dianthus Therapeutics stock have an average target of 54.33, with a low estimate of 36 and a high estimate of 84. The average target predicts an increase of 152.11% from the current stock price of 21.55.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 12, 2025.
Analyst Ratings
The average analyst rating for Dianthus Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 3 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $36 | Buy | Reiterates | $36 | +67.05% | Mar 12, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $84 | Strong Buy | Reiterates | $84 | +289.79% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +85.61% | Mar 12, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +85.61% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
3.59M
from 6.24M
Decreased by -42.50%
Revenue Next Year
2.90M
from 3.59M
Decreased by -19.00%
EPS This Year
-3.47
from -2.55
EPS Next Year
-3.73
from -3.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.9M | 7.2M | 55.6M | ||
| Avg | 3.6M | 2.9M | 9.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.2% | 101.3% | 1,815.4% | ||
| Avg | -42.5% | -19.0% | 240.2% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.63 | -3.06 | -2.69 | ||
| Avg | -3.47 | -3.73 | -4.21 | ||
| Low | -3.99 | -4.51 | -6.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.